Management of lateral pelvic lymph nodes in rectal cancer

Gloria Chang; Wissam J Halabi; Fadwa Ali

doi:10.1002/jso.27317

Management of lateral pelvic lymph nodes in rectal cancer

J Surg Oncol. 2023 Jun;127(8):1264-1270. doi: 10.1002/jso.27317.

Authors

Gloria Chang¹, Wissam J Halabi², Fadwa Ali¹

Affiliations

¹ Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
² Department of Surgery, Enloe Medical Center, Chico, California, USA.

PMID: 37222691
DOI: 10.1002/jso.27317

Abstract

Lateral pelvic lymph node (LPLN) involvement occurs in 10%-25% of rectal cancer cases. Total mesorectal excision (TME) with routine LPLN dissection (LPLND) is predominantly applied in Japan whereas TME with neoadjuvant treatment are used in the West. LPLND is a morbid procedure and minimally invasive techniques may help reduce its morbidity. Selective lateral pelvic node dissection with TME following neoadjuvant treatment achieves acceptable disease-free and overall survival.

Keywords: lateral pelvic lymph nodes; pelvic lymphadenopathy; rectal adenocarcinoma; rectal cancer.

Publication types

Review

MeSH terms

Dissection
Humans
Japan
Lymph Node Excision
Lymph Nodes* / surgery
Pelvis*
Rectal Neoplasms* / surgery